#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

A novel coronavirus (SARS-CoV-2) and COVID-19


Authors: Milan Trojánek 1,2,3;  Vyacheslav Grebenyuk 1,3;  Kristýna Herrmannová 3;  Tomáš Nečas 4;  Jana Gregorová 5;  Martin Kucbel 6;  Robin Šín 7;  Hana Roháčová 3;  František Stejskal 1,3,8,9
Authors‘ workplace: Klinika infekčních nemocí 2. LF UK a Nemocnice Na Bulovce, Praha 1;  Katedra infekčního lékařství, IPVZ, Praha 2;  Klinika infekčních, parazitárních a tropických nemocí, Nemocnice Na Bulovce, Praha 3;  Pediatrické oddělení, Krajská nemocnice T. Bati, Zlín 4;  Oddělení klinické farmacie, Nemocnice Na Bulovce, Praha 5;  Radiodiagnostická klinika, Nemocnice Na Bulovce, Praha 6;  Klinika infekčních nemocí a cestovní medicíny LF UK a FN Plzeň 7;  Ústav imunologie a mikrobiologie 1. LF UK a VFN, Praha 8;  Infekční oddělení, Krajská nemocnice Liberec 9
Published in: Čas. Lék. čes. 2020; 159: 55-66
Category: Review Article

Overview

By the end of 2019 the first cases of severe pneumonia of unknown origin were reported in Wuhan, China. The causative agent was identified as a novel b-coronavirus SARS-CoV-2 and the disease was named COVID-19. Since the beginning of 2020, the infection has spread worldwide, which led the WHO to declare COVID-19 a public health emergency of international concern and to characterize the current situation as a pandemic.

The transmission occurs mainly via respiratory droplets and the incubation period ranges from 2 to 14 days. Most cases are mild, but some patients develop severe pneumonia with acute respiratory distress, septic shock and multi-organ failure. The most common symptoms include fever, dry cough, myalgia and shortness of breath. Characteristic laboratory findings are normal white blood cell count or mild leukopenia, marked lymphopenia, in severe cases elevated CRP, procalcitonin, LDH, and D-dimer are commonly found. Typical imaging findings include multifocal peripherally distributed ground-glass opacities or consolidations, interlobular septal thickening, crazy paving appearance and cystic changes. The overall case fatality rate is estimated to range from 1 to 3 %, however, it is dependent on age and underlying medical comorbidities. Current potential treatment options include hydroxychloroquine, remdesivir, lopinavir/ritonavir and convalescent plasma.

Keywords:

Coronaviruses – SARS-CoV-2 – COVID-19 – pneumonia


Sources
  1. Burrell CJ, Howard CR, Murphy FA (eds.). Fenner and White’s Medical Virology. Coronaviruses. Academic Press, 2016: 437–446.
  2. Ye Z-W, Yuan S, Yuen K-S et al. Zoonotic origins of human coronaviruses. Int J Biol Sci 2020; 16(10): 1686–1697.
  3. Zhu N, Zhang D, Wang W et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020; 382: 727–733.
  4. Singhal T. A review of coronavirus disease 2019 (COVID-19). Indian J Pediatr 2020; 87: 281–286.
  5. Sohrabi C, Alsafi Z, O’Neill N et al. World Health Organization declares global emergency: a review of the 2019 novel coronavirus (COVID-19). Int J Surg 2020; 76: 71–76.
  6. ECDC. COVID-19. Dostupné na: www.ecdc.europa.eu/en/covid-19-pandemic
  7. Han Q, Lin Q, Jin S et al. Recent insights into 2019-nCoV: a brief but comprehensive review. J Infect 2020 Apr; 80(4): 373–377.
  8. Tang X, Wu C, Li X et al. On the origin and continuing evolution of SARS-CoV2. Nat Sci Rev 2020; nwaa036, doi: 10.1093/nsr/nwaa036/5775463.
  9. Thomas-Rüddel D, Winning J, Dickmann P et al. Coronavirus disease 2019 (COVID-19): update for anesthesiologists and intensivists March 2020. Anaesthesist 2020 Mar 24; 1–10, doi: 10.1007/s00101-020-00760-3.
  10. van Doremalen N, Bushmaker T, Morris DH et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med 2020; 382: 1564–1567.
  11. WHO. Rational use of personal protective equipment for coronavirus disease 2019 (COVID-19) and considerations during severe shortages. Interim guidance. WHO, 2020. Dostupné na: www.who.int/publications-detail/rational-use-of-personal-protective-equipment-for-coronavirus-disease-(covid-19)-and-considerations-during-severe-shortages
  12. Rabi FA, Al Zoubi MS, Kasabeh GD et al. SARS-CoV-2 and coronavirus disease 2019: What we know so far. Pathogens 2020 Mar 20; 9(3): 231.
  13. Zhou F, Yu T, Du R et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China  a retrospective cohort study. Lancet 2020 Mar 28; 395(10229): 1054–1062.
  14. Wölfel R, Corman VM, Guggemos W et al. Virological assessment of hospitalized cases of coronavirus disease 2019. Nature 2020 Apr 1, doi: 10.1038/s41586-020-2196-x.
  15. Cheng ZJ, Shan J. 2019 Novel coronavirus: where we are and what we know. Infection 2020 Apr; 48(2): 155–163.
  16. Park M, Cook AR, Lim JT et al. A systematic review of COVID-19 epidemiology based on current evidence. J Clin Med 2020; 9(4): E967.
  17. Zhang J, Litvinova M, Wang W et al. Evolving epidemiology and transmission dynamics of coronavirus disease 2019 outside Hubei province, China: a descriptive and modelling study. Lancet Infect Dis 2020 Apr 2, doi: 10.1016/S1473-3099(20)30230-9.
  18. Lauer SA, Grantz KH, Bi Q et al. The incubation period of 2019-nCoV from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020 Mar 10, doi: 10.7326/M20-0504.
  19. Du Z, Xu X, Wu Y et al. The serial interval of COVID-19 from publicly reported confirmed cases. Emerg Infect Dis 2020 Mar 19; 26(6), doi: 10.3201/eid2606.200357.
  20. Huang C, Wang Y, Li X et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395: 497–506.
  21. Wang W, Xu Y, Gao R et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA 2020 Mar 11; e203786.
  22. Yang Y, Yang M, Shen C et al. Evaluating the accuracy of different respiratory specimens in the laboratory diagnosis and monitoring the viral shedding of 2019-nCoV infections. medRxiv 2020 Feb 17, doi: 10.1101/2020.02.11.20021493v2.
  23. Zhang W, Du RH, Li B et al. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. Emerg Microbes Infect 2020; 9: 386–389.
  24. Zhao J, Yuan Q, Wang H et al. Antibody Responses to SARS-CoV-2 in Patients of Novel Coronavirus Disease 2019. Clin Infect Dis 2020 Mar 28; ciaa344.
  25. Okba NMA, Muller MA, Li W et al. SARS-CoV-2 specific antibody responses in COVID-19 patients. Emerg Infect Dis 2020 Apr 8; 26(7), doi: 10.3201/eid2607.200841.
  26. Li X, Geng M, Peng Y et al. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal 2020 Mar 5, doi: 10.1016/j.jpha.2020.03.001.
  27. Xu Z, Shi L, Wang Y et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020 Apr; 8(4): 420–422.
  28. Guan W-J, Ni Z-Y, Hu Y et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020 Apr 30; 382(18): 1708–1720.
  29. Wang D, Hu B, Hu C et al. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020; 323 (11): 1061–1069.
  30. Zhang JJ, Dong X, Cao YY et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy 2020 Feb 19, doi: 10.1111/all.14238. 
  31. Borges do Nascimento IJ, Cacic N, Abdulazeem HM et al. Novel coronavirus infection (COVID-19) in humans: a scoping review and meta-analysis. J Clin Med 2020 Mar 30; 9(4): E941.
  32. Lechien JR, Chiesa-Estomba CM, De Siati DR et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur Arch Otorhinolaryngol 2020 Apr 6; 1–11, doi: 10.1007/s00405-020-05965-1.
  33. Liu W, Tao Z-W, Wang L et al. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chin Med J (Engl) 2020 May 5; 133 (9): 1032–1038.
  34. Lu X, Zhang L, Du H et al. SARS-CoV-2 infection in children. N Engl J Med 2020 Apr 23; 382: 1663–1665.
  35. Dong Y, Mo X, Hu Y et al. Epidemiological characteristics of 2143 pediatric patients with 2019 coronavirus disease in China. Pediatrics 2020, doi: 10.1542/peds.2020-0702.
  36. Henry BM, Lippi G, Plebani M. Laboratory abnormalities in children with novel coronavirus disease 2019. Clin Chem Lab Med 2020, doi: 10.1515/cclm-2020-0272. 
  37. Di Mascio D, Khalil A, Saccone G et al. Outcome of coronavirus spectrum infections (SARS, MERS, COVID-19) during pregnancy: a systematic review and meta-analysis. Am J Obstet Gynecol MFM 2020 Mar 25; 100107.
  38. Chen H, Guo J, Wang C et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet 2020 Mar 7; 395(10226): 809–815.
  39. Kimberlin DW, Stagno S. Can SARS-CoV-2 infection be acquired in utero? More definitive evidence is needed. JAMA 2020 Mar 26, doi: 10.1001/jama.2020.4868. 
  40. Kümpel P, Holub M, Roháčová H, Plíšek S. Doporučený postup SIL ČLS JEP léčby pacientů s prokázanou infekcí COVID 19. Společnost infekčního lékařství ČLS JEP, 2020. Dostupné na: www.infekce.cz/Covid2019/DP-SIL-covid12p.pdf
  41. Phua J, Weng L, Ling L et al. Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations. Lancet Respir Med 2020 May; 8(5): 506–517.
Labels
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain management
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#